Literature DB >> 3830730

Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a CEA-producing human colon tumour xenograft.

P J Harwood, J Boden, R B Pedley, G Rawlins, G T Rogers, K D Bagshawe.   

Abstract

The dynamics of distribution of radiolabelled F(ab')2 fragments of a monoclonal anti-CEA antibody have been studied in the nude mouse bearing a CEA-producing human colon carcinoma. Our results showed that the fragment was rapidly cleared from all normal organs reaching about 1% of that injected by 24 hr. Specific tumour localization occurred as early as 2 hr after injection and was complete by 4 hr. The amount of fragment localized in tumour was 4% of the injected dose, equivalent to that obtained with the intact antibody. Greatly improved tumour:normal tissue ratios were obtained with the fragment compared to intact IgG. However, the residence time of the fragment was much shorter (24 hr) than that of intact antibody (more than 3 days). Tumour localization indices suggested that fragments were superior to intact IgG at locating tumour specifically. The specificity indices based on lung, spleen and liver were much higher than those for intact antibody, reflecting the lack of Fc-receptor binding of fragments and their reduced excretion by these organs. The 'fragment index' enabled tumour:normal tissue ratios for the fragment and intact IgG to be compared. Together with the distribution study at different time points, this simplifies the task of defining a 'time window' in which tumour imaging and therapy might be optimal.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3830730     DOI: 10.1016/0277-5379(85)90247-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  7 in total

1.  Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.

Authors:  B M Mueller; R A Reisfeld; S D Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

Review 2.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 3.  Intratumour factors influencing the access of antibody to tumour cells.

Authors:  L M Cobb
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Dose-dependent localisation and potential for therapy of F(ab')2 fragments against CEA studied in a human tumour xenograft model.

Authors:  G T Rogers; P J Harwood; R B Pedley; J Boden; K D Bagshawe
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

5.  Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.

Authors:  R B Pedley; J A Boden; R Boden; R Dale; R H Begent
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

6.  Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives.

Authors:  H Jackson; L Bacon; R B Pedley; E Derbyshire; A Field; J Osbourn; D Allen
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

7.  Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.

Authors:  D Marshall; R B Pedley; R G Melton; J A Boden; R Boden; R H Begent
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.